Cellectar Biosciences FY EPS $(4.05) Misses $(3.91) Estimate; Cash & Cash Equivalents Of $19.9M Sufficient To Fund Operations Into Q4 2023
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(4.05) per share which missed the analyst consensus estimate of $(3.91) by 3.58 percent. This is a 6.9 percent increase over losses of $(4.35) per share